Analysis of peripheral blood leukocytes in patients with cyclosporine A-induced gingival hyperplasia

Journal of Periodontology

Volumn 69, Issue 12, 1998, Pages 1435-1439

  Cebeci, Írfan ^a   Kantarci, Alpdoǧan ^a   Gürel, Nuray ^b   Adin, Suzan ^b   Tuncer, Özen ^a   Çarin, Mahmut ^b   Badur, Selim ^b   Firatli, Erhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE

Author keywords

Cyclosporine; Flow cytometry; Gingiva hyperplasia; Lymphocyte; Monocyte; Natural killer cell

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GINGIVA HYPERPLASIA; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; NATURAL KILLER CELL; TOOTH PLAQUE;

EID: 0032449019     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.1998.69.12.1435     Document Type: Article

References (33)

1. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: A new antilymphocyte agent. Agent Action 1976;6: 468-475.
2. Larsson EL. Cyclosporin A and dexamethasone suppress T-cell responses by selectively acting at distinct sites of the triggering process. J Immunol 1980;124:2828-2836.
3. Shevach EM. The effects of cyclosporin A on the immune system. Ann Rev Immunol 1985;3:397-423.
4. Lillehoj HS, Malek TR, Shevach EM. Differential effect of cyclosporin A on the expression of T and B lymphocyte activation antigens. J Immunol 1984;133:244-251.
5. Page EH, Wexler DM, Guenther LC. Cyclosporin A. J Am Acad Dermatol 1986;14:785-791.
6. Faulds D, Goa KL, Benfield P. Cyclosporin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
7. Klintmalm G, Iwatsuki S, Starzl TE. Cyclosporin A hepatoxicity in 66 renal allograft recipients. Transplantation 1981;32:488-489.
8. Ota B, Bradley M. Side effects of cyclosporinc in 100 renal allograft recipients. Transplant Proc 1983;15:3150-3156.
9. Rateitschak-Plüss EM, Hefti A, Lörtscher R, Thiel G. Initial observation that cyclosporin A induces gingival enlargement in man. J Clin Periodontol 1983;10:237-246.
10. Daley TD, Wysocki GP, May C. Clinical and pharmacological correlations in cyclosporin-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62:417-421.
11. Savage NW, Seymour GJ, Robinson MF. Cyclosporin A-induced gingival enlargement. J Periodontol 1986;58:475-480.
12. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med 1991;2:103-107.
13. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:107-110.
14. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol 1991;18:107-110.
15. Pernu HE, Hannele Pernu LM, Knuuttila LE. Effect of periodontal treatment on gingival overgrowth among cyclosporinc A-treated renal transplant recipients. J Periodontol 1993;64:1098-1100.
16. Thomason JM, Seymour RA, Rice N. The prevalance and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodiontol 1993;20:37-40.
17. Hassell TM, Burtner AP, McNeal D, Smith RG. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000 1994; 6:68-78.
18. Pernu HE, Knuuttila MLE, Huttunen KRS, Tilikainen ASK. Drug-induced gingival overgrowth and Class Il major histocompatibility antigens. Transplantation 1994;57:1811-1813.
19. Somacarrera ML, Hernmandez, JA, Moskow BS. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol 1994;65: 671-675.
20. Thomason JM, Seymour RA, Ellis JS, et al. Iatrogenic gingival overgrowth in cardiac transplantation. J Periodontol 1995;66:742-746.
21. Cebeci I, Kantarci A, Firatli E. et al. Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporin A. J Clin Periodontol 1996;23:737-742.
22. Cebeci I, Kantarci A, Firatli E. Çarin M, Tuncer Ö. The effect of verapamil on the prevalence and severity of cyclosporine-induced gingival overgrowth in renal allogratt recipients. J Periodontol 1996;67:1201-1205.
23. Iacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol 1997;68:73-83.
24. Seymour RA, Smith DG, Turnbull DN. The effect of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodoontol 1985;12:413-419.
25. Silness J, Löe H. Penodontal disease in pregnancy; II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
26. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533-551.
27. Shaw LM. Advances in cyclosporinc pharmacy, measurement, and therapeutic monitoring. Clin Chem 1989;35:1299-1308.
28. Hiesland PC, Mekler P. Mechanism of action: Cyclosporin- and prolactin-mediated control of immunity. Progress Aller 1986;38:239-247.
29. Weiss A, Imboden JB. Cell surface molecules and early events in human T lymphocyte activation. Adv Immunol 1987;41:1-38.
30. Ashwell JD, Klausner RD. Genetic and mutational analysis of the T-cell antigen receptor. Ann Rev Immunol 1990;8:139-167.
31. Hess AD, Colombani PM. Mechanism of action: In vitro studies. Progress Aller 1986;38:198-221.
32. Herberman RB, Reynolds CW, Ortaldo J. Mechanisms of cytotoxicity by natural killer cells. Ann Rev Immunol 1986;4:651-680.
33. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47: 187-376.